Key facts
- This page summarizes Ann D. Rhoads's Form 4 filing for iTeos Therapeutics, Inc. (ITOS).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 15 Jun 2023, 19:56.
Ann D. Rhoads - 13 Jun 2023 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)
- Reporting relationship
- Director
- Issuer ticker
- ITOS
- Reported as of
- 13 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 15 Jun 2023, 19:56:32 UTC
- Prior SEC filing
- 12 Jun 2023
- Next SEC filing
- 30 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Adi Osovsky, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ann D. Rhoads filed Form 4 for iTeos Therapeutics, Inc. (ITOS) on 15 Jun 2023.
Change
- Previous filing in this sequence was filed on 12 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ITOS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +22,383
- Change %
- Price
- $0.000000
- Shares after
- 22,383
- Date
- 13 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 22,383
- Exercise price
- $14.77
* marks a reported price that did not pass the local price check.